Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03798912 | A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform | PHASE1 | COMPLETED | 62 | — | — | Jul 1, 2019 | Feb 1, 2020 | Oct 7, 2020 | - | — |
| Name | Type | Description |
|---|---|---|
| RaniPill capsule containing octreotide | COMBINATION_PRODUCT | Administration of a RaniPill capsule loaded with 100 mcg of octreotide. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule. |